Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,521 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.
Twelves C, Hoekman K, Bowman A, Vermorken JB, Anthoney A, Smyth J, van Kesteren C, Beijnen JH, Uiters J, Wanders J, Gomez J, Guzmán C, Jimeno J, Hanauske A. Twelves C, et al. Among authors: beijnen jh. Eur J Cancer. 2003 Sep;39(13):1842-51. doi: 10.1016/s0959-8049(03)00458-1. Eur J Cancer. 2003. PMID: 12932661 Clinical Trial.
Phase I study of vintriptol, a tryptophan ester of vinblastine.
Oosterkamp HM, Vlasveld LT, Wanders J, Beijnen JH, van Tellingen O, Dubbelman AC, Simonetti GP, Franklin HR, Vermorken JB, Ten Bokkel Huinink WW. Oosterkamp HM, et al. Among authors: beijnen jh. Eur J Cancer. 1991;27(10):1222-6. doi: 10.1016/0277-5379(91)90085-r. Eur J Cancer. 1991. PMID: 1835590 Clinical Trial.
A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion.
van Kesteren C, Mathĵt RA, López-Lázaro L, Cvitkovic E, Taamma A, Jimeno JM, Guzman C, Schellens JH, Misset JL, Brain E, Hillebrand MJ, Rosing H, Beijnen JH. van Kesteren C, et al. Among authors: beijnen jh. Cancer Chemother Pharmacol. 2001 Dec;48(6):459-66. doi: 10.1007/s002800100368. Cancer Chemother Pharmacol. 2001. PMID: 11800026
Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue.
Schöffski P, Herr A, Vermorken JB, Van den Brande J, Beijnen JH, Rosing H, Volk J, Ganser A, Adank S, Botma HJ, Wanders J. Schöffski P, et al. Among authors: beijnen jh. Eur J Cancer. 2002 Apr;38(6):807-13. doi: 10.1016/s0959-8049(02)00022-9. Eur J Cancer. 2002. PMID: 11937315 Clinical Trial.
Analysis of Ecteinascidin 743, a new potent marine-derived anticancer drug, in human plasma by high-performance liquid chromatography in combination with solid-phase extraction.
Rosing H, Hillebrand MJ, Jimeno JM, Gómez A, Floriano P, Faircloth G, Cameron L, Henrar RE, Vermorken JB, Bult A, Beijnen JH. Rosing H, et al. Among authors: beijnen jh. J Chromatogr B Biomed Sci Appl. 1998 Jun 12;710(1-2):183-9. doi: 10.1016/s0378-4347(98)00143-1. J Chromatogr B Biomed Sci Appl. 1998. PMID: 9686886
Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Rosing H, Hillebrand MJ, Jimeno JM, Gómez A, Floriano P, Faircloth G, Henrar RE, Vermorken JB, Cvitkovic E, Bult A, Beijnen JH. Rosing H, et al. Among authors: beijnen jh. J Mass Spectrom. 1998 Nov;33(11):1134-40. doi: 10.1002/(SICI)1096-9888(1998110)33:11<1134::AID-JMS730>3.0.CO;2-S. J Mass Spectrom. 1998. PMID: 9835068 Clinical Trial.
1,521 results